Abstract: A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where the treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation of the alkaline agent to the enteric polymer is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? E ? C ? L ) .

Abstract: A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the ICL, containing an enteric polymer. The relation of alkaline agent to enteric polymer is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? ECL ) . The ? ICL ? has ? a ? thickness ? of ? about ? 22 ? ? ? m ? or ? more .

Abstract: A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where the treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation of the alkaline agent to the enteric polymer is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? E ? C ? L ) .

Abstract: A dosage form contains a) a core, containing a biologically active ingredient, which is stable to a degree of at least 95% at a pH of 3 for 2 hours at 22° C.; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation in percent of the alkaline agent in the ICL to the enteric polymer in the ECL is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? ? ECL ) .

Abstract: The invention provides preparations comprising at least one polyunsaturated fatty acid salt for use in enhancing the solubility in aqueous media for a pharmaceutical or nutraceutical active ingredient in comparison to the pharmaceutical or nutraceutical active ingredient alone by at least 100%, preferably at least 300%. Moreover, a method for preparing a pharmaceutical or nutraceutical dosage form comprising at least one polyunsaturated fatty acid salt and at least one pharmaceutical or nutraceutical active ingredient is disclosed.